百蕊颗粒与利巴韦林治疗小儿手足口病的临床疗效对比

Comparison of clinical efficacy of Bairui granule and ribavirin in the treatment of children's hand-foot-mouth disease

目的对比百蕊颗粒与利巴韦林治疗小儿手足口病的临床疗效。方法选择湖南省儿童医院2016年2月至2017年2月收治的100例小儿手足口病患儿,按抗病毒药物使用的不同分为利巴韦林治疗组及百蕊颗粒治疗组,每组各50例。观察两组治疗前后肿瘤坏死因子-α(TNF-α)、白细胞介素(IL-1β、IL-6)的变化,两组治疗后退热时间、手足疱疹消退时间、口腔溃疡愈合时间,以及两组不良反应发生率。结果百蕊组不良反应发生率明显低于利巴韦林组,差异有统计学意义(6.0%比20.0%,P<0.05);百蕊组各症状消失时间均明显短于利巴韦林组,差异有统计学意义[退热时间(d):1.50±0.20比2.35±0.25;手足疱疹消退时间(d):2.30±0.50比3.45±0.35;口腔溃疡愈合时间(d):2.50±0.25比4.00±0.40,均P<0.05];治疗后两组炎症细胞因子均较治疗前明显降低,差异均有统计学意义[利巴韦林组:TNF-α:62.41±5.49比112.48±5.32;IL-1β:25.29±1.41比59.64±1.36;IL-6:33.18±1.32比54.20±1.25,百蕊组:TNF-α:41.77±5.53比112.50±5.40;IL-1β:18.33±1.37比60.20±1.35;IL-6:28.97±1.33比54.25±1.30,均P<0.05],且治疗后百蕊颗粒组显著低于利巴韦林组。结论百蕊颗粒治疗小儿手足口病的临床疗效优于利巴韦林,且安全性高,可作为优选治疗方案推广使用。

Objective To investigate the efficacy of Bairui granule and ribavirin in the treatment of children＇s hand-foot-mouth disease. Methods One hundred children with pediatric hand-foot-mouth disease were enrolled in the Children＇s Hospital of Hunan Province from February 2016 to February 2017. According to the different treatments, 100 children were divided into ribavirin treatment group and ribavirin plus Balrui granule treatment group （Bairui group）, with 50 cases in each group. The levels of tumor necrosis factor-α （TNF-α） and interleukin （IL-1β, IL-6） in the two groups were observed before and after treatment. The time of fever clearance, the fading time of rashes on hands and feet, the healing time of oral ulcers, and the incidence of adverse reactions in each group were recorded. Results The incidence of adverse reactions in Bairui group was significantly lower than that in the ribavirin group （6.0% vs. 20.0%, P 〈 0.05）. The disappearance time of the symptoms was significantly shorter than that of the ribavirin group [fever clearance time （day）： 1.50 ± 0.20 vs. 2.35 ± 0.25; rashes on hands and feet fading time （day）： 2.30 ± 0.50 vs. 3.45 ± 0.35; oral ulcer healing time （day）： 2.50± 0.25 vs. 4.00 ± 0.40; all P 〈 0.05）. After treatment, the levels of inflammatory cytokines in the two groups were significantly lower than those before treatment [ribavirin group： TNF-α （μg/L）： 62.41 ± 5.49 vs. 112.48 ± 5.32, IL-1β （μg/L）： 25.39 ± 1.31 vs. 59.64±1.36; IL-6 （μg/L）： 33.18±1.32 vs. 54.20±1.25, Bairui group： TNF-α （μg/L）： 41.77±5.53 vs. 112.50 ± 5.40; IL-1β （μg/L）： 18.33 ± 1.37 vs. 60.20 ± 1.35; IL-6 （μg/L）： 28.97 ± 1.33 vs. 54.25 ± 1.30; all P 〈0.05）, and the levels of the treatment group were significantly lower than those of ribavirin group. Conclusion The efficacy of Baise granule combined with ribavirin in the treatment of pediatric hand, foot and mouth disease is good, and it is safe and can be used as a preferred treatment.